Compare Bristol-Myers Squibb Co (BMY) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Block Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.63 (market cap $116.30B), while Block Inc trades at $82.53 (market cap $47.61B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.4× Block Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Block Inc pays none. Which is the better fit depends on your goals.
| BMY | XYZ | |
|---|---|---|
Market Cap | $116.30B | $47.61B |
Sector | Health | Technology |
52-Week High | $62.37 | $81.11 |
52-Week Low | $42.60 | $49.04 |
Enterprise Value | $152.24B | $42.48B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Block (XYZ) trades at $78.72, up 1.84% today, with a bullish technical outlook and strong analyst support (26 buy ratings). Recent earnings beat expectations in Q1 2026, though net income margin narrowed to 3.3% in 2025. The company faces a $45 million settlement over Cash App fraud allegations but continues to invest in AI and Square growth.
The stock offers upside to the $88.53 consensus target, driven by earnings momentum and AI initiatives, but risks include regulatory scrutiny, rising credit losses, and volatile cash flow. Investors should weigh solid long-term growth prospects against near-term execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
